Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

Journal of Clinical Oncology

Volumn 24, Issue 9, 2006, Pages 1443-1448

  Ceresoli, Giovanni Luca ^a   Zucali, Paolo A ^b   Favaretto, Adolfo G ^b   Grossi, Francesco ^b   Bidoli, Paolo ^b   Del Conte, Guido ^b   Ceribelli, Anna ^b   Bearz, Alessandra ^b   Morenghi, Emanuela ^b   Cavina, Raffaele ^b   Marangolo, Maurizio ^b   Soto Parra, Hector J ^b   Santoro, Armando ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; DIURETIC AGENT; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; TREATMENT OUTCOME;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEUTROPENIA; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 33645449947     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3190     Document Type: Article

References (33)

1. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999
2. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 117:54-65, 1999
3. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al: Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128: 138-146, 2004
4. Baldini EH: External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 14:543-548, 2004
5. Robinson BW, Lake RA: Advances in malignant mesothelioma. N Engl J Med 353:1591-1603, 2005
6. Steele JPC, Klabatsa A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16:345-351, 2005
7. Berghmans T, Paesmans M, Lalami Y, et al: Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121, 2002
8. Mbidde EK, Harland SJ, Calvert AH, et al: Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18:284-285, 1986
9. Raghavan D, Gianoutsos P, Bishop J, et al: Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151-154, 1990
10. Vogelzang NJ, Goutsou M, Corson JM, et al: Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukaemia Group B. Cancer Chemother Pharmacol 27:239-242, 1990
11. Hazarika M, White RM, Booth BP, et al: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982-992, 2005
12. Scagliotti GV, Shin DM, Kindler HL, et al: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561, 2003
13. Thodtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multi-targeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17:3009-3016, 1999
14. Hughes A, Calvert P, Azzabi A, et al: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544, 2002
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003
16. Rusch VW: Pemetrexed and cisplatin for malignant pleural mesothelioma: A new standard of care? J Clin Oncol 21:2629-2630, 2003
17. Van Meerbeeck JP, Gaafar R, Manegold C, et al: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889, 2005
18. Teicher BA, Chen V, Shin C, et al: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023, 2000
19. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma: From the International Mesothelioma Interest Group. Chest 108:1122-1128, 1995
20. National Cancer Institute: Common Toxicity Criteria Manual, version 2.0, June 1, 1999. http://ctep.cancer.gov/reporting/ctc.html
21. Fleiss JL: Statistical methods for rates and proportions (ed 2). New York, NY, Wiley and Sons, 1981, pp. 13-15
22. Leemis LM, Trivedi KS: A comparison of approximate interval estimators for the Bernoulli Parameter. Am Stat 50:63-68, 1996
23. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
25. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152, 1998
26. Agresti A: A survey of exact inference for contingency tables. Stat Sci 7:131-177, 1992
27. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
28. Ceribelli A, Cecere FL, Milella M, et al: Severe rhabdomyolysis associated with pemetrexed-based chemotherapy. Lancet Oncol (in press)
29. Byrne MJ, Nowak AK: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260, 2004
30. Oxnard GR, Armato SG, Salgia R, et al: Development of response criteria for mesothelioma based on a mathematical model. J Clin Oncol 23: 664S, 2005 (suppl, abstr 7176)
31. Ceresoli GL, Zucali PA, Van Hemert R, et al: Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotherapy by quantitative assessment of standard uptake value (SUV). Lung Cancer 49;S219, 2005 (suppl 2, abstr P-394)
32. Fennell D, Steele J, Sheaff M, et al: Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49:S220, 2005 (suppl 2, abstr P-397)
33. Manegold C, Symanowski J, Gatzemeier U, et al: Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16:923-927, 2005